TPTX » Topics » Maximize Value of Versatile Lead Compounds

This excerpt taken from the TPTX 8-K filed Feb 14, 2008.

Maximize Value of Versatile Lead Compounds

 

AMPA/kainate receptor antagonists

 

·                  Conduct a Clinical Guidance meeting with the U.S. Food and Drug Administration (FDA) in the first half of the year to discuss the efficacy results from the recently completed Phase II clinical trial of tezampanel in acute migraine headache. As reported last October, tezampanel met its primary endpoint of headache pain relief in a double-blind, placebo-controlled, Phase IIb trial in 306 patients with acute migraine. Depending on the outcome of the meeting, the company intends to conduct an end-of-Phase II meeting with the FDA in the second half of 2008.

 

(more)

 



 

·                  Initiate a Phase II trial of tezampanel in muscle spasticity and rigidity secondary to spinal cord trauma in the second half of the year. This trial will be the company’s first for tezampanel in a non-pain indication and is intended to demonstrate the potential utility of tezampanel for indications beyond migraine and chronic pain.

 

·                  Complete the ongoing Phase I maximum tolerated dose trial of NGX426, the oral prodrug of tezampanel, in the first half of the year.

 

·                  Initiate a Phase I single-dose trial of NGX426 in a capsaicin model for neuropathic pain in the first half of the year. The purpose of this trial is to show that tezampanel may be an effective analgesic when administered orally as NGX426.  Tezampanel has been shown in six Phase II trials to be an effective analgesic when administered parentally.

 

·                  Initiate a Phase I multiple dose trial of NGX426 in the second half of the year.

 

Muscarinic agonist

 

·                  Initiate a Phase II trial of NGX267 in xerostomia, or dry mouth, secondary to Sjogren’s syndrome in the first half of the year. The company has demonstrated the safety of single and multiple doses of NGX267 in three Phase I trials involving healthy volunteers. In two of these studies, statistically significant increases in salivary flow were demonstrated.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki